Evidence map›Paper›PMID 30869058›Full record

ArticleEpidemiology and infection2019

Epidemiology and genotypic characterisation of dissemination patterns of uropathogenic Escherichia coli in a community.

M Matsukawa, M Igarashi, H Watanabe, L Qin, M Ohnishi, J Terajima, S Iyoda, T Morita-Ishihara, K Tateda, Y Ishii and 3 more

Abstract read
In one paragraph

Article in Epidemiology and infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Detection of amoxicillin-resistant and multidrug-resistantMicrobiology (Reading, England) · 2026
    Article
  2. Genomic profiling of ESBL/AmpC-producingFrontiers in microbiology · 2026
    Article
  3. Article
  4. Article
  5. Molecular characterization of uropathogenicJournal of veterinary science · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. ESBL-Producing and Non-ESBL-ProducingInfection and drug resistance · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Natural Bred εAntibiotics (Basel, Switzerland) · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

M MatsukawaDepartment of Urology,Takikawa Municipal Hospital,Takikawa,Japan.ORCID 0000-0002-3637-8385
M IgarashiDepartment of Urology,Takikawa Municipal Hospital,Takikawa,Japan.
H WatanabeDepartment of Infection Control and Prevention,Kurume University School of Medicine,Kurume,Japan.
L QinDepartment of Infection Control and Prevention,Kurume University School of Medicine,Kurume,Japan.
M OhnishiDepartment of Bacteriology I,National Institute of Infectious Diseases,Tokyo,Japan.
J TerajimaDepartment of Bacteriology I,National Institute of Infectious Diseases,Tokyo,Japan.
S IyodaDepartment of Bacteriology I,National Institute of Infectious Diseases,Tokyo,Japan.
T Morita-IshiharaDepartment of Bacteriology I,National Institute of Infectious Diseases,Tokyo,Japan.
K TatedaDepartment of Microbiology and Infectious Diseases,Toho University School of Medicine,Tokyo,Japan.
Y IshiiDepartment of Microbiology and Infectious Diseases,Toho University School of Medicine,Tokyo,Japan.
T SagaDepartment of Microbiology and Infectious Diseases,Toho University School of Medicine,Tokyo,Japan.
K AokiDepartment of Microbiology and Infectious Diseases,Toho University School of Medicine,Tokyo,Japan.
R A BonomoMedical Service,Louis Stokes Cleveland Veterans Affairs Medical Center,Cleveland, Ohio,USA.

Funding

Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
A Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4M
NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI100560
6 · The paper itself

Abstract

To characterise the dissemination patterns of uropathogenic Escherichia coli (UPEC) in a community, we conducted a study utilising molecular and fundamental descriptive epidemiology. The subjects, consisted of women having community-acquired acute urinary tract infection (UTI), were enrolled in the study from 2011 to 2012. UPEC isolates were subjected to antibacterial-susceptibility testing, O serogrouping, phylotyping, multilocus-sequence typing with phylogenetic-tree analysis and pulsed-field-gel electrophoresis (PFGE). From the 209 unique positive urinary samples 166 UPEC were isolated, of which 129 were fully susceptible to the tested antibiotics. Of the 53 sequence types (STs), the four most prevalent STs (ST95, ST131, ST73 and ST357) accounted for 60% of all UPEC strains. Antimicrobial resistance was less frequently observed for ST95 and ST73 than for the others. A majority of rare STs and a few common STs constituted the diversity pattern within the population structure, which was composed of the two phylogenetically distinct clades. Eleven genetically closely related groups were determined by PFGE, which accounted for 42 of the 166 UPEC isolates, without overt geo-temporal clustering. Our results indicate that a few major lineages of UPEC, selected by unidentified factors, are disseminated in this community and contribute to a large fraction of acute UTIs.

Indexed as

GenotypeCommunity-Acquired InfectionsEscherichia coli InfectionsFemaleHumansMicrobial Sensitivity TestsMolecular EpidemiologyMolecular TypingSerotypingUrinary Tract InfectionsUropathogenic Escherichia colimolecular epidemiologyphylogenetic analysisurinary tract infectionuropathogenic Escherichia coli

Identifiers

PMID30869058
PMCPMC6518783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.